摘要目的 探讨血清人附睾蛋白4(HE4)和癌抗原125(CA125)单独和联合使用在预测卵巢癌发病风险中的价值.方法 75例卵巢癌患者(卵巢癌组)分别应用酶联免疫吸附法和电化学发光法检测血清HE4和CA125水平,并与132例良性卵巢疾病患者(良性卵巢疾病组)以及30例健康女性(对照组)进行比较,并计算两者单独和联合预测卵巢癌发病风险的特异度和灵敏度,绘制受试者工作特征(ROC)曲线.结果 卵巢癌组血清HE4和CA125水平明显高于良性卵巢疾病组和对照组(P＜0.05).两者都可以预测卵巢癌的发生,HE4在预测卵巢癌发病风险方面较CA125具有较明显优势(ROC曲线下面积分别为0.966和0.905).HE4在浆液性腺癌中阳性表达率最高,为100.0%(42/42).HE4阳性诊断卵巢癌的灵敏度为86.7%(65/75),HE4和/或CA125阳性诊断卵巢癌的灵敏度为93.3%(70/75),两者比较差异无统计学意义(P＞0.05).结论 血清HE4比CA125能够更好地预测卵巢癌的发生,HE4可以作为预测卵巢癌发病风险的指标,HE4联合CA125不能够明显提高卵巢癌的检出率.

abstractsObjective To explore the value of serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) in the prediction of ovarian cancer onset risk. Methods Petected the expression of HE4 by enzyme linked immunosorbent assay (ELISA) and CA 125 by electrochemiluminescence (ECL) in serum of 75 samples of ovarian cancer (ovarian cancer group),132 samples of ovarian benign disease (ovarian benign disease group) and 30 samples of healthy women (control group),calculated the sensitivity and specificity of HE4 and CA125 in the prediction of ovarian cancer onset risk,and drew receiver operating characteristic (ROC) curve. Results The expression of serum HE4 and CA125 were both higher in ovarian cancer group than those in ovarian benign disease group and control group (P ＜ 0.05 ). HE4 was a better index in the prediction of ovarian cancer onset risk than CA 125 (ROC area under curve was 0.966 and 0.905 respectively). The expression of HE4 was various in different pathological types,serous ovarian adenocarcinoma had the highest expression of HE4 (100.0% ,42/42). The sensitivity of diagnosing ovarian cancer by HE4 was 86.7%(65/75), 93.3%(70/75) by HE4 combining and/or CA125,there was no significant difference(P＞0.05).Conclusion Serum HE4 could be a good index of predicting the onset risk of ovarian cancer,the combination of HE4 and/or CA125 could not increase the sensitivity of prediction of ovarian cancer significantly.